Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy

American Heart Journal

Volumn 170, Issue 2, 2015, Pages 223-230

  Kramer, Christopher M ^a   Appelbaum, Evan ^b   Desai, Milind Y ^c   Desvigne Nickens, Patrice ^d   DiMarco, John P ^a   Friedrich, Matthias G ^e   Geller, Nancy ^d   Heckler, Sarahfaye ^f   Ho, Carolyn Y ^g   Jerosch Herold, Michael ^g   Ivey, Elizabeth A ^f   Keleti, Julianna ^d   Kim, Dong Yun ^d   Kolm, Paul ^f   Kwong, Raymond Y ^g   Maron, Martin S ^h   Schulz Menger, Jeanette ⁱ   Piechnik, Stefan ^j   Watkins, Hugh ^j   Weintraub, William S ^f   Wu, Pan ^f   Neubauer, Stefan ^j   more..

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

^f Christiana Center for Outcomes Research   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GALECTIN 3; GENOMIC DNA; MATRIX METALLOPROTEINASE; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN I;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE REGISTRY; DNA DETERMINATION; ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; GENETIC ANALYSIS; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HIGH RISK POPULATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SCAR FORMATION; STUDY DESIGN; ADOLESCENT; ADULT; AGED; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; GENETIC SCREENING; HEALTH; HEART STROKE VOLUME; HEART VENTRICLE; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; REGISTER; SEVERITY OF ILLNESS INDEX; TIME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GLOBAL HEALTH; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MORBIDITY; PROSPECTIVE STUDIES; REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; YOUNG ADULT;

EID: 84939569120     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.05.013     Document Type: Article

References (29)

1. B.J. Maron Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy Circulation 121 2010 445 456
2. C. Semsarian, J. Ingles, M.S. Maron, and et al. New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol 65 2015 1249 1254
3. B.J. Maron Hypertrophic cardiomyopathy JAMA 287 10 2002 1308 1320
4. H. Watkins, H. Ashrafian, and C. Redwood Inherited cardiomyopathies N Engl J Med 364 17 2011 1643 1656
5. B.J. Maron, P. Spirito, W.K. Shen, and et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy JAMA 298 4 2007 405 412
6. M. Maron Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy J Cardiovasc Magn Reson 14 1 2012 13
7. J.J. Green, J. Berger, C.M. Kramer, and et al. Prognostic value of cardiac magnetic resonance late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy JACC Cardiovasc Imaging 5 2012 370 377
8. R.H. Chan, B.J. Maron, I. Olivotto, and et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy Circulation 130 6 2014 484 495
9. G. Moravsky, E. Ofek, H. Rakowski, and et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR JACC Cardiovasc Imaging 6 5 2013 587 596
10. M. Jerosch-Herold, D.C. Sheridan, J.D. Kushner, and et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy Am J Physiol Heart Circ Physiol 295 3 2008 H1234 H1242
11. A.S. Flett, M.P. Hayward, M.T. Ashworth, and et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis Circulation 122 2 2010 138 144
12. C.Y. Ho, S.A. Abbasi, T.G. Neilan, and et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy Circ Cardiovasc Imaging 6 3 2013 415 422
13. P.M. Elliott, A. Anastasakis, M.A. Borger, and et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy Eur Heart J 35 39 2014 2733 2779
14. B.J. Gersh, B.J. Maron, R.O. Bonow, and et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary J Am Coll Cardiol 58 25 2013 2703 2738
15. J.P. Kaski, P. Syrris, M.T.T. Esteban, and et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy Circ Cardiovasc Genet 2 5 2009 436 441
16. I. Olivotto, F. Girolami, M.J. Ackerman, and et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy Mayo Clin Proc 83 6 2008 630 638
17. C.Y. Ho, B. Lopez, O.R. Coelho-Filho, and et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy N Engl J Med 363 6 2010 552 563
18. I. Olivotto, F. Girolami, R. Sciagrà, and et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations J Am Coll Cardiol 58 8 2011 839 848
19. S. Piechnik, V. Ferreira, E. Dall'Armellina, and et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold J Cardiovasc Magn Reson 12 1 2010 69
20. J. Schulz-Menger, D.A. Bluemke, J. Bremerich, and et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing J Cardiovasc Magn Reson 15 1 2013 35
21. J. Todd, B. Freese, A. Lu, and et al. Ultrasensitive flow-based immunoassays using single-molecule counting Clin Chem 53 11 2007 1990 1995
22. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, and et al. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35 Eur Heart J 30 2009 162 169
23. F. Harrell Jr. Regression modeling strategies with applications to linear models, logistic regression and survival analysis 2001 Springer New York
24. P. Peduzzi, J. Concato, A.R. Feinstein, and et al. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates J Clin Epidemiol 48 12 1995 1503 1510
25. D.M. Witten, and R. Tibshirani Testing significance of features by lassoed principal components Ann Appl Stat 3 2008 986 1012
26. D. Schoenfeld Partial residuals for the proportional hazards regression model Biometrical 69 1982 239 241
27. J.J. Goeman L1 penalized estimation in the Cox Proportional Hazards Model Biom J 52 1 2010 70 84
28. G. Ambler, S. Seaman, and R.Z. Omar An evaluation of penalised survival methods for developing prognostic models with rare events Stat Med 31 11-12 2012 1150 1161
29. G. Molenberghs, and M.G. Kenward Missing data in clinical studies 2007 John Wiley & Sons West Sussex, UK